Clinical trial · no report yet · Phase 3
BRUIN CLL-321
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- NCT04666038 ↗
- Active not recruiting
- Loxo Oncology, Inc.
- 62 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 32 | |
| Podcasts | 24 | |
| X threads | 6 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
- Interventions
- Pirtobrutinib; Idelalisib; Bendamustine; Rituximab
- Arms
- Arm A - Pirtobrutinib · Experimental
- Arm B - Idelalisib plus Rituximab or Bendamustine plus Rituximab · Active comparator
- Enrollment
- 238
- Primary outcomes
- Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)
- Sponsor
- Loxo Oncology, Inc. with Eli Lilly and Company
- Start
- Mar 9, 2021
- Primary completion
- Aug 29, 2023
- Results posted
- Yes
- Registry record
- NCT04666038 · updated Apr 24, 2026
Publications
linked from the registry- Loubert A, Creel K, Bhandari NR, Hess LM, Ruppert AS, Abada P, Regnault A, Payakachat N. Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library. J Patient Rep Outcomes. 2026 Jun 22;10(1):109. doi: 10.1186/s41687-026-01126-w. PubMed 42329537
- Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, Grzasko N, Follows G, Matrai Z, Sanna A, Qiu L, Feng R, Hua VM, Jurczak W, Ritgen M, Yi S, Bosch F, Coombs CC, Bao K, Patel V, Liu B, Compte L, Guntur A, Wang DY, Hill M, Leow CC, Ghia P, Barr PM. Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). J Clin Oncol. 2025 Aug;43(22):2538-2549. doi: 10.1200/JCO-25-00166. Epub 2025 Jun 6. PubMed 40479620